Early allograft dysfunction (EAD) after liver transplantation (LT) is associated with inferior graft survival. EAD is more prevalent in grafts from donation after circulatory death (DCD). However, accurate prediction of liver function remains difficult because of the lack of specific biomarkers. Recent experimental and clinical studies highlight the potential of hepatocyte-derived microRNAs (miRNAs) as sensitive, stable, and specific biomarkers of liver injury. The aim of this study was to determine whether miRNAs in graft preservation fluid are predictive for EAD after clinical LT and in an experimental DCD model. Graft preservation solutions of 83 liver grafts at the end of cold ischemia were analyzed for miRNAs by reverse transcription polymerase chain reaction. Of these grafts, 42% developed EAD after transplantation. Results were verified in pig livers (n 5 36) exposed to different lengths of warm ischemia time (WIT). The absolute miR-122 levels and miR-122/miR-222 ratios in preservation fluids were significantly higher in DCD grafts (P 5 0.001) and grafts developing EAD (P 5 0.004). In concordance, the miR-122/miR-222 ratios in perfusion fluid correlate with serum transaminase levels within the first 24 hours after transplantation. Longterm graft survival was significantly diminished in grafts with high miR-122/miR-222 ratios (P 5 0.02). In the porcine DCD model, increased WIT lead to higher absolute miR-122 levels and relative miR-122/miR-222 ratios in graft perfusion fluid (P 5 0.01 and P 5 0.02, respectively). High miR-122/miR-222 ratios in pig livers were also associated with high aspartate aminotransferase levels after warm oxygenated reperfusion. In conclusion, both absolute and relative miR-122 levels in graft preservation solution are associated with DCD, EAD, and early graft loss after LT. As shown in a porcine DCD model, miRNA release correlated with the length of WITs.
Because of a growing organ shortage, the use of marginal donors has increased in recent years. However, in liver transplantation (LT) the use of these extended criteria donors (ECDs) has also resulted in the prevalence of early allograft dysfunction (EAD), primary nonfunction (PNF), and early graft loss. (1) (2) (3) PNF of the liver is a life-threatening condition that is thought to be caused by microcirculation injury in the immediate postoperative period. Emergency retransplantation of the liver is necessary because of the extreme high mortality of PNF. Hereby, the prevalence of PNF has decreased over the last decades. Nonetheless, it occurs in 2%-6% of all LTs. (4) (5) (6) EAD occurs in 20%-25% of all LTs and is less severe but remains an important determinant of graft and overall patient survival in the long term. (7, 8) The definition of EAD proposed by Olthoff et al. includes high early aminotransferase levels (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] of <2000 U/L within the first 7 postoperative days), cholestasis (bilirubin 10 mg/dL on day 7), and coagulopathy (international normalized ratio [INR] 1.6 on day 7). These criteria have been mainly validated for grafts from heartbeating donors. (7, 9) Although the pathophysiology of EAD or PNF is not completely understood and is likely multifactorial, several risk factors for diminished graft function after transplantation have been reported. The main factors are high donor age, donation after circulatory death (DCD) allografts, high recipient Model for End-Stage Liver Disease (MELD) score at the time of transplantation, a high degree of graft steatosis, small allograft size, long operative time, and high intraoperative transfusion requirements. (8, 10) However, because of the growing demand for liver grafts, allografts which do not meet the traditional criteria for transplantation (ECDs, EAD) are used more frequently. (11, 12) In order to improve the quality of these EAD grafts and to reduce the posttransplantation risks for the receiver, machine perfusion as a preservation technique has received increasing attention. (13) (14) (15) (16) (17) (18) (19) Machine preservation may also provide new opportunities to assess graft quality during the preservation period prior to transplantation and aid in the decision making of whether to transplant the organ. (13) (14) (15) (16) (17) (18) (19) Reliable parameters or biomarkers for functional assessment of livers during preservation in either machine perfusion or static cold storage are of paramount importance yet are relatively unexplored. (8, (20) (21) (22) (23) (24) (25) (26) (27) (28) In the search for viable biomarkers, microRNAs (miRNAs) have gained interest due to their low complexity, stability, and organ specificity. Many studies have shown that miRNAs released in biofluids like serum, urine, and bile can be used as sensitive and accurate biomarkers. (29) (30) (31) (32) (33) (34) (35) (36) They are associated with a variety of pathologic conditions and control many cellular processes including tissue injury and repair. (24, 29, (37) (38) (39) Therefore, circulating miRNAs might be helpful contributors in the existing decision-making models to either accept or decline a potential donor liver for transplantation in order to optimize graft and patient survival.
Previous studies have reported the use of perfusates to predict graft survival and graft dysfunction by measuring lactate dehydrogenase (LDH), AST, and ALT levels. Our group investigated miRNAs in liver graft perfusates and proved their stability in samples with up to 24 hours of storage at room temperature. (37) In this study by Verhoeven et al., (37) an association was shown between high cholangiocyte-derived miRNAs in liver graft preservation solution and ischemic-type biliary lesions after transplantation, suggesting the link between miRNA release before transplantation and posttransplantation complications. (40) However, no studies on miRNA biomarkers in the preservation liquid for EAD or early graft loss after LT have been reported.
This study aims to determine whether liver-specific miRNAs in perfusion liquids during graft preservation are predictive of the development of EAD after transplantation. Furthermore, the predictive value of miRNAs on longterm graft survival was investigated. The hypothesis was, based on current literature on liverspecific miRNAs in serum and their relation to liver function, that higher levels are correlated to damage and subsequent decreased graft function after transplantation. Because of increased levels of hepatocellular damage in DCD grafts, a correlation of high miRNA levels to longer warm ischemia times (WITs) was expected. In order to verify this assumption and to minimize variations in the pre-preservation variables, we included the results of an experimental DCD porcine model in the interpretation of the results. Clinical implications of these results will be discussed.
Patients and Methods
The Medical Ethical Committee of the Erasmus University Medical Center approved the use of donor materials, and all patients provided informed consent for the use of clinical information for medical research. The animals described in the experimental model were treated in accordance to national and international guidelines on animal welfare. Explanations on study design, definition of EAD, sample collection and processing, RNA isolation, reverse transcription polymerase chain reaction, experimental design of the porcine model, and statistical analyses are listed in the Supplemental Material. 16 (6) 18 (5) 17 (6) 0.25 Total WIT, minutes, median (SEM)
Results

PATIENT CHARACTERISTICS
29 (10) 32 (9) 30 (10) NOTE: Data are given as mean 6 SD and n (%) unless otherwise noted. *P < 0.05. † P < 0.01.
In this study, it is confirmed that graft origin is a predictor for EAD. A total of 7 out of 48 (15%) of the non-EAD patients received a DCD graft while that was the case for 15 out of 35 (43%) in the EAD group (P 5 0.006). Total CIT or WIT did not differ between the non-EAD and EAD group (387 and 29 minutes versus 426 and 32 minutes, respectively). Furthermore, receiving a graft from a male donor was associated with EAD after transplantation (P 5 0.03). According to the definition of EAD, recipients with delayed graft function had significantly higher AST and ALT levels in the first 24 hours after transplantation.
RELATIVE miR-122 IN BIOPSIES AND PERFUSATES
Relative miR-122 levels in biopsies (n 5 34) were compared between grafts that developed EAD (n 5 17) and grafts with a good initial function (n 5 17). Individual miR-122 levels were not significantly increased in grafts with poor function after transplantation (Fig. 1A, left panel) . However, in these same 34 patients, relative miR-122 was significantly different in perfusates (Fig. 1A, right panel) .
Individual miRNAs in perfusates were analyzed in a bigger cohort of 83 patients and compared between grafts that developed EAD and non-EAD grafts (Fig.  1B, left panel) . Levels of miR-122 were significantly increased in grafts with poor function after transplantation. To relative miRNA-levels within each sample and control for variations in RNA quantities, we used the ratio of hepatocyte-derived miRNA/cholangiocyte-derived miRNA of miR-122/miR-222 as previously described. (37) Grafts which developed EAD after transplantation had significantly higher miRNA ratios, compared with those that did not develop EAD, because of high miR-122 levels and relative low amounts of miR-222 (Fig. 1B, right panel) . Relative levels of miR-222 were not significantly different between both groups (P 5 0.46, data not shown).
Univariate analysis indicates high individual miRNA levels and miRNA ratios as risk factors to develop EAD (Table 2) . In multivariate analysis, FIG. 1. miRNA release is increased in grafts which develop EAD after transplantation. (A) In a subset (n 5 34), we analyzed relative miRNA levels in biopsies. However, miRNA levels were not significantly different between grafts that developed EAD (n 5 17) and grafts that had good posttransplantation function (non-EAD group, n 5 17). (B) miR-122 in the perfusates of the same 34 grafts showed a significant difference between EAD and non-EAD grafts. (C) Comparison of relative miRNA levels in perfusates (n 5 83) obtained from EAD (n 5 35) and non-EAD grafts (n 5 48). (D) miRNA levels were normalized to miR-222 levels using a ratio. The miR-122/miR-222 ratios were significantly different between EAD and non-EAD grafts. Mean 6 SEM is shown. *P < 0.05; **P < 0.01.
individual and relative high miR-122 remains important in the development of EAD, independently of the type of graft or sex of the donor. In this table, the discriminative power of miRNAs in perfusate is indicated as C-statistics and ranges from 0.677 to 0.742.
RELATIVE miRNA LEVELS IN PERFUSATES FROM DCD VERSUS DONATION AFTER BRAIN DEATH LIVERS
DCD livers are more prone to develop EAD than grafts from brain dead donors as is known from earlier literature and is demonstrated in our univariate and multivariate analysis. In our cohort of 83 transplanted grafts, DCD livers showed higher miRNA levels in perfusates, suggesting increased damage to the hepatocytes in these grafts. Figure 2A shows the differences in miR-122 levels in donation after brain death (DBD) versus DCD livers (P 5 0.005). Figure 2B shows the differences in miR-122/miR-222 ratios between DBD and DCD grafts that did or did not develop EAD (P 5 0.001). Ratios are increased regardless of whether the graft was obtained from a DCD or a DBD donor (DCD-non-EAD versus DCD-EAD, P 5 0.04; DBD-non-EAD versus DBD-EAD, P 5 0.035; DBD-EAD versus DCD-EAD, P 5 0.047; DBD-non-EAD versus DCD-non-EAD, P 5 0.02). Although a clear trend was found, no significant difference was observed in length of the first WIT and miR-122/miR-222 levels (data not shown, P 5 0.07). This may be due to the lack of objective measurements of the length of WIT in the clinical setting.
INCREASED PERFUSATE miRNA RATIOS ARE ASSOCIATED WITH EARLY GRAFT LOSS
We found significantly higher miR-122/miR-222 ratios in perfusates of livers that were lost within the first 12 months after transplantation. Furthermore, relative high miRNA ratios were associated with inferior 
FIG. 2. miRNA ratios are increased in DCD grafts and in DCD grafts which developed EAD. (A)
Comparison of the miR-122/ miR-222 ratio in perfusates obtained from DBD grafts (n 5 61) and DCD grafts (n 5 22; P 5 0.001). (B) A subanalysis in the DBD group in patients who developed EAD showed significant higher levels than those with good organ function (n 5 41; P 5 0.045). In the DCD group, a significant difference was seen between the EAD and non-EAD group (P 5 0.04). Similar results are present within the DCD group of EAD patients (n 5 15), which had significantly higher miR-122/miR-222 levels compared with DBD/EAD (n 5 20; P 5 0.047). Furthermore, a significant difference in ratios was seen in miR-122/miR-222 levels between DBD/ non-EAD and DCD/EAD (P 5 0.001). *P < 0.05; **P < 0.01.
graft survival on the long term (Fig. 3) . However, relative miR-122 levels were not significant for survival in the first year (P 5 0.10) or in the long term (P 5 0.07).
PERFUSATE miRNA LEVELS CORRELATE WITH POSTTRANSPLANT SERUM AST AND ALT LEVELS
To combine our observations with clinical outcome in patients after transplantation, AST (U/L) and ALT (U/L) levels 24 hours after transplantation in patient serum were correlated to miRNA ratios in perfusates. Figure 4 shows a significant correlation between miR-122/miR-222 ratio and AST (Fig. 4 , left) and ALT (Fig. 4 , right) levels in serum of recipients 24 hours after transplantation. These correlations were also significant for miR-122 levels alone with AST, ALT, and LDH (P 5 0.01, r 2 5 0.28; P 5 0.007, r 2 5 0.30; P 5 0.045, r 2 5 0.22, respectively). The miR-122/miR-222 ratio was similarly correlated to LDH levels on day 1 (P 5 0.006, r 2 5 0.30, data not shown).
VALIDATION OF miR-122 IN AN EXPERIMENTAL DCD MODEL
To confirm the observation that miR-122 levels correlate with AST and can be useful as a determinant for EAD, we analyzed liver perfusates after procurement in an experimental porcine model of donation after cardiac death. This model was used to standardize the length of the WIT. Warm ischemia during normal liver procurement was mimicked by clamping the The group with high levels of AST (>1500 U/L) after 3 hours of warm perfusion showed significantly higher miR-122/ miR-222 levels during perfusion. *P < 0.05; **P < 0.01. minutes of WIT), and cluster 3 (60 and 120 minutes of WIT). Levels of miR-122 during HMP showed a significant increase in groups with more hepatocyte injury (Fig. 5B) . miR-122/miR-222 showed a similar increase with a marked distinction between clusters 3 and 1 and between clusters 3 and 2. During warm reperfusion, a rise in AST levels (after 3 hours) was observed in the 3 groups: 1092 U/L (SD, 953.2 U/L), 1819 U/L (SD, 1396 U/L), and 2494 U/L (SD, 2376 U/L), respectively. These findings correlated with ischemic damage on a pathological scale of liver biopsies as reported by Liu et al. (data previously published). (41) Levels of miR-122 in the cold perfusion liquid after 60 minutes showed a significant correlation with AST levels at the end of the warm reperfusion episode/ experiment (r 2 5 0.38; P 5 0.02). This correlation was even stronger between the miR-122/miR-222 ratio and AST levels (Fig. 5C ) and was comparable to the clinical data (P 5 0.005; r 2 5 0.46). Furthermore, we divided the livers into 2 groups of grafts with AST levels <1500 U/L and >1500 U/L after reperfusion, equivalent to the clinical transaminase threshold. We saw higher miR-122 and miR-122/miR-222 levels in the samples of livers with AST levels of >1500 U/L, consistent with our human data. miR-122 as an individual marker showed similar results ( Fig. 5D ; P 5 0.02).
Discussion
In this study, we demonstrate that high miR-122 levels and relative high miR-122/miR-222 ratios in perfusion liquids are associated with EAD and poor graft survival after LT. As reported in several other studies, miRNA-122 was abundantly expressed in the liver and is correlated to conventional biomarkers as AST, ALT, and LDH. (42, 43) Relative miR-122 and ratios of miR-122/miR-222 during graft preservation are significantly higher in both DCD and DBD grafts that developed EAD than in those that had a normal postoperative organ function. Furthermore, miR-122/ miR-222 ratios are significantly higher in grafts that are lost within the first year after transplantation. Elevated miR-122/miR-222 ratios are all associated with poor graft survival in the long term independently of EAD after transplantation. We also found an association between miRNA levels in perfusates and serum AST and ALT levels in the first 24 hours after transplantation. Therefore, miRNAs present in the perfusion liquid might be a marker for hepatocyte injury during preservation. To support our clinical data, we used an experimental model in which porcine livers were exposed to increased degrees of hepatic injury before hypothermic machine preservation. After a standardized period of warm ischemia, our results were similar to our clinical findings: miR-122 and ratios of miR-122/miR-222 were related to AST concentrations in the perfusion liquids and were higher in the groups with more severe hepatic injury. Consistent with our results, several other studies have found an increase in miRNA levels in hepatic injury. Even though the mechanism involved in the release of miRNAs is still not clear, miR-122 has been reported to have a role as a biomarker in the prediction of liver function and injury, including in viral hepatitis, cirrhosis, and hepatocellular carcinoma. (35, 44) miRNA-122 in particular has been reported to be specific to the liver and therefore might be more specific to hepatocyte injury than other classic liver enzymes as AST, ALT, and LDH. (42, 43, 45, 46) Even though the mechanism involved in the release of miRNAs is still not clear, miR-122 has been reported to have a critical role in regulation of the lipid homeostasis by controlling cholesterol synthesis and lipoprotein in the liver. (35, 44, (47) (48) (49) (50) Furthermore, besides measurement of miR-122 levels as a biomarker in several causes of injury of the liver, it has been shown to function as a tumor suppressor in hepatocellular carcinoma.
(51) Additionally, it might therefore even be the target of therapy in hepatocellular carcinoma and viral hepatitis. (52, 53) miR-222 has not been investigated in the same extent, but studies show that it is abundant in biliary epithelium. (36) Others have also reported on high miR-222 levels in patients with primary sclerosing cholangitis and biliary atresia. (54, 55) In the early detection of hepatic injury, miRNAs in perfusates have several advantages. Perfusates are obtained from total vascular perfusion during preservation and therefore represent the whole liver. Sampling bias can therefore be minimized compared with tissue biopsies, for example. As we showed in our data, there was a significant difference in miRNA levels in perfusates, but this difference was not observed in biopsies. This might indicate a better representation of miRNA levels in perfusates than those in biopsies due to the more complete representation or the whole organ of miRNAs in perfusates. Additionally, perfusate samples are taken in a noninvasive manner and do no further harm to the organ. Furthermore, perfusates represent graft quality prior to transplantation independent of recipient factors, where the liver is the only possible source of the released miRNAs. (29, (35) (36) (37) (38) 56) Our earlier observation that miRNAs in perfusate, like in many biofluids, are very stable adds to the advantage of exploring miRNAs for their potential as biomarkers. (37) Data of the present study are consistent with these earlier findings and provide a more specific insight into the properties of miRNAs as biomarkers. However, several limitations should be considered in this study. Although miR-122 levels in both pigs and humans were increased in liver grafts with increased hepatic injury after preservation in cold perfusion liquids, the results from our experimental study are not completely comparable to the reported clinical findings. Although both miR-122 and miR-222 are present in porcine livers, much less is known about their function and the effects of hepatic injury in pigs. Furthermore, human miRNA levels were measured in samples after an average of 6.5 hours of static cold storage and might therefore not be completely comparable to the porcine samples collected after 1 hour of machine perfusion. Additionally, livers in our experimental model were not transplanted after preservation, but a warm reperfusion period was performed to mimic the clinical situation. We also acknowledge the fact that isolated warm reperfusion might not be comparable with real transplantation and that 2 hours of reperfusion might not be long enough to mimic the full process of ischemia/reperfusion injury and EAD. Nonetheless, we consider the hepatic injury due to warm ischemia clinically relevant and comparable to damage to the liver in the human setting, however, performed in a standardized, experimental manner. Therefore, the obtained results supported our hypothesis due to similar developments in AST, hepatic injury, and miRNA levels.
Lastly, it is unclear whether miRNAs in serum and biopsies differ from those in perfusate liquids, and in this study, we used only a very small selection of miRNAs which was based on the current literature. (56, 57) Therefore, more studies regarding the properties of miRNAs and specifically those in perfusion liquids are necessary to validate our hypothesis that miRNAs in perfusates can be used as biomarkers of organ function prior to transplantation. Although miR-122/miR-222 ratios are significantly different between both groups and on a biological level related to liver damage, the predictive value of the levels is insufficient as a single biomarker. Therefore, further research is required to identify a miRNA profile that can predict which grafts are likely to develop complications postoperatively.
In conclusion, these findings identify hepatocytespecific miR-122 and the miR-122/miR-222 ratio in preservation liquids during static cold storage of liver grafts as independent factors related to EAD and graft survival. These potential biomarkers may aid in the assessment of graft function of an isolated liver graft prior to transplantation. Furthermore, our findings regarding miR-122 and miR-122/miR-222 ratios as possible biomarkers may ultimately help in the identification of therapies during graft preservation and thereby improve graft function.
